Trial
NCT01764997
An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sanofi
Collaborators
Regeneron Pharmaceuticals
Condition
Rheumatoid Arthritis
Intervention
Sarilumab
Why stopped
Due to small number of participants entering randomization. Not a safety issue.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-07-27